<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene K417N;Q493H;N501Y literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.K417N;Q493H;N501Y</span> literature reference collection</h1>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> 100% of the 5 8‑month‑old male R3P1-E4 antibody treated mice suvived 14 days after infection while only 60% the control group mice survived 5 days post infection. <br/> (<a href="https://doi.org/10.1186/s13578-022-00794-7" class="lit_link">Li et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Lung viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~2266x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.<br/> (<a href="https://doi.org/10.1186/s13578-022-00794-7" class="lit_link">Li et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Trachea viral loads were tested by qRT‑PCR and RNA scope at 3 dpi on 5 8‑month‑old male mice and there was a ~750x fold drop in the R3P1-E4 antibody in comparison to  the IgG control.<br/> (<a href="https://doi.org/10.1186/s13578-022-00794-7" class="lit_link">Li et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
